ID   C84
AC   CVCL_5250
DR   cancercelllines; CVCL_5250
DR   CancerTools; 151760
DR   Cell_Model_Passport; SIDM01548
DR   ColonAtlas; C84
DR   Cosmic; 948841
DR   Cosmic; 986011
DR   Cosmic; 995388
DR   Cosmic; 1043803
DR   Cosmic; 1223133
DR   Cosmic; 1312295
DR   Cosmic; 1479568
DR   Cosmic; 2301962
DR   Cosmic; 2760065
DR   Cosmic; 2800572
DR   DepMap; ACH-001460
DR   ECACC; 12022902
DR   GEO; GSM1346864
DR   GEO; GSM1374424
DR   GEO; GSM1448203
DR   IARC_TP53; 21748
DR   PRIDE; PXD005354
DR   PRIDE; PXD005355
DR   Wikidata; Q54808265
DR   Ximbio; 151760
RX   PubMed=8197130;
RX   PubMed=8464898;
RX   PubMed=10051639;
RX   PubMed=10737795;
RX   PubMed=16418264;
RX   PubMed=18258742;
RX   PubMed=20570890;
RX   PubMed=20606684;
RX   PubMed=23272949;
RX   PubMed=24755471;
RX   PubMed=25926053;
RX   PubMed=29101300;
CC   Part of: AstraZeneca Colorectal cell line (AZCL) panel.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   HLA typing: A*02,03 (PubMed=8464898).
CC   Microsatellite instability: Stable (MSS) (PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg283Ter (c.847C>T); ClinVar=VCV000184999; Zygosity=Unspecified (PubMed=24755471; DepMap).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg640Trp (c.1918C>T); ClinVar=VCV000428132; Zygosity=Unspecified (PubMed=24755471; DepMap).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Arg1450Ter (c.4348C>T); ClinVar=VCV000194585; Zygosity=Unspecified (PubMed=24755471; DepMap).
CC   Sequence variation: Mutation; HGNC; 914; B2M; Simple; p.Asp54Asn (c.160G>A); ClinVar=VCV001479725; Zygosity=Heterozygous (PubMed=8197130; DepMap).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (PubMed=20570890; PubMed=24755471; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Unspecified (PubMed=16418264; PubMed=24755471; DepMap).
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Cecum; UBERON=UBERON_0001153.
ST   Source(s): DepMap; ECACC; PubMed=25926053
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 11,12
ST   D16S539: 11,13 (DepMap)
ST   D16S539: 13 (ECACC; PubMed=25926053)
ST   D18S51: 17
ST   D21S11: 33.2
ST   D3S1358: 15,18
ST   D5S818: 12
ST   D7S820: 11
ST   D8S1179: 13,15
ST   FGA: 19,20
ST   Penta D: 14
ST   Penta E: 7,8
ST   TH01: 7,9.3
ST   TPOX: 8,9
ST   vWA: 14,15
DI   NCIt; C5543; Cecum adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   67Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 32
//
RX   PubMed=8197130; DOI=10.1073/pnas.91.11.4751;
RA   Bicknell D.C., Rowan A.J., Bodmer W.F.;
RT   "Beta 2-microglobulin gene mutations: a study of established
RT   colorectal cell lines and fresh tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994).
//
RX   PubMed=8464898; DOI=10.1073/pnas.90.7.2842;
RA   Browning M.J., Krausa P., Rowan A.J., Bicknell D.C., Bodmer J.G.,
RA   Bodmer W.F.;
RT   "Tissue typing the HLA-A locus from genomic DNA by sequence-specific
RT   PCR: comparison of HLA genotype and surface expression on colorectal
RT   tumor cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 90:2842-2845(1993).
//
RX   PubMed=10051639; DOI=10.1073/pnas.96.5.2316;
RA   Efstathiou J.A., Liu D., Wheeler J.M., Kim H.C., Beck N.E., Ilyas M.,
RA   Karayiannakis A.J., Mortensen N.J., Kmiot W., Playford R.J.,
RA   Pignatelli M., Bodmer W.F.;
RT   "Mutated epithelial cadherin is associated with increased
RT   tumorigenicity and loss of adhesion and of responsiveness to the
RT   motogenic trefoil factor 2 in colon carcinoma cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 96:2316-2321(1999).
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=16418264; DOI=10.1073/pnas.0510146103;
RA   Liu Y., Bodmer W.F.;
RT   "Analysis of P53 mutations and their expression in 56 colorectal
RT   cancer cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).
//
RX   PubMed=18258742; DOI=10.1073/pnas.0712176105;
RA   Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.;
RT   "Cell growth, global phosphotyrosine elevation, and c-Met
RT   phosphorylation through Src family kinases in colorectal cancer
RT   cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z.-S., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.M.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=23272949; DOI=10.1186/1755-8794-5-66;
RA   Schlicker A., Beran G., Chresta C.M., McWalter G., Pritchard A.,
RA   Weston S., Runswick S., Davenport S., Heathcote K., Castro D.A.,
RA   Orphanides G., French T., Wessels L.F.A.;
RT   "Subtypes of primary colorectal tumors correlate with response to
RT   targeted treatment in colorectal cell lines.";
RL   BMC Med. Genomics 5:66.1-66.15(2012).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=29101300; DOI=10.15252/msb.20177701;
RA   Frejno M., Zenezini Chiozzi R., Wilhelm M., Koch H., Zheng R.-S.,
RA   Klaeger S., Ruprecht B., Meng C., Kramer K., Jarzab A., Heinzlmeir S.,
RA   Johnstone E., Domingo E., Kerr D., Jesinghaus M., Slotta-Huspenina J.,
RA   Weichert W., Knapp S., Feller S.M., Kuster B.;
RT   "Pharmacoproteomic characterisation of human colon and rectal
RT   cancer.";
RL   Mol. Syst. Biol. 13:951-951(2017).
//